Healthcare Sales & Marketing Network News: squamous cell carcinoma

Searching News Database: squamous cell carcinoma

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jun 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2022
Alercell Starts to Distribute Human Papilloma Virus (HPV) DNA Test
Diagnostics Product Launch

HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Jun 2021
Cardinal Health(TM) Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK(R) Pediatric Indication
Biopharmaceuticals Radiology Oncology FDA

HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Mar 2021
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jan 2021
Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
Devices Personnel

HSMN NewsFeed - 23 Dec 2020
Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Dec 2020
Almirall announces FDA approval of Klisyri(R) (tirbanibulin), a new innovative topical treatment for actinic keratosis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Jun 2020
Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
Devices Oncology Venture Capital

HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2019
Rakuten Medical Opens Two New Offices In The Netherlands And Taiwan, Adding New Jobs To Strengthen And Expand Its Global Presence
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2019
Sensus Healthcare Awarded Brachytherapy Products Agreement with Premier
Devices Oncology Dermatology Group Purchasing

HSMN NewsFeed - 1 Mar 2019
Rakuten Aspyrian Announces Name Change to Rakuten Medical
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Dec 2018
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Sep 2018
Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer
Devices Radiology Oncology Venture Capital

HSMN NewsFeed - 23 Aug 2018
Rakuten Aspyrian Raises $150 Million in Series C Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 Aug 2018
Alpha Tau's High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United States
Devices Oncology Regulatory

HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Apr 2018
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Sep 2017
Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jun 2017
Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 May 2017
Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Apr 2017
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer with Radiation Therapy
Devices Oncology

HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Jan 2017
PENTAX Medical Expands Interventional Endoscopy Offering with Acquisition of C2 Therapeutics
Devices Mergers & Acquisitions

HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Nov 2016
Inovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Diagnostics Oncology Regulatory

HSMN NewsFeed - 28 Mar 2016
Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Feb 2016
Lion Biotechnologies Names Steven A. Fischkoff Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Jan 2016
CARsgen Therapeutics Completes $30 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 15 Oct 2015
Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Sep 2014
Navidea’s Lymphoseek(R) Recommended by CHMP for European Approval in Sentinel Lymph Node Detection for Melanoma, Breast and Certain Head and Neck Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2014
Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2014
Navidea Biopharmaceuticals’ Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Mar 2014
First US patients receive Esteya electronic brachytherapy for skin cancer
Devices Oncology

HSMN NewsFeed - 19 Feb 2014
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Dec 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Dec 2013
FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek(R) for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 2 Oct 2013
Nucletron, an Elekta Company, Receives US FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer
Devices Oncology FDA

HSMN NewsFeed - 10 Apr 2013
U.K. Clinic Anticipating New Era of Radiotherapy Speed and Precision with Elekta’s New Versa HD System
Devices Oncology

HSMN NewsFeed - 14 Nov 2012
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jun 2012
Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI(R) (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2012
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Apr 2012
Mobile Skin Cancer Treatment Now Features Xstrahl Superficial Radiation System
Devices Dermatology Oncology Distribution

HSMN NewsFeed - 23 Apr 2012
OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
Devices Drug Delivery Oncology

HSMN NewsFeed - 20 Feb 2012
Plexxikon Announces European Approval of Zelboraf(R) for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Jan 2012
LEO Pharma Announces That Picato(R) (ingenol mebutate) gel has Been Approved by US FDA for Once-Daily, 2 or 3 day Treatment of Actinic Keratoses
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Jan 2012
FDA Approves Picato(R) (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
Biopharmaceuticals Drug Delivery Dermatology FDA

HSMN NewsFeed - 21 Nov 2011
BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien
Devices Mergers & Acquisitions

HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Aug 2011
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
Biopharmaceuticals Oncology Personalized Medicine FDA

HSMN NewsFeed - 20 Jul 2011
Neoprobe Establishes European Business Unit
Devices Diagnostics Oncology

HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Biopharmaceuticals Diagnostics Personalized Medicine

HSMN NewsFeed - 10 Dec 2010
BioVex Commences OncoVEXGM-CSF Phase 3 Trial in Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Aug 2010
T-Ray Science, Inc. Announces Reorganization
Devices Diagnostics Oncology Personnel

HSMN NewsFeed - 15 Jul 2010
Provectus Pharmaceuticals Reports Achieved Milestones for First Half of 2010, Recent Developments and Plans for the Remainder of the Year to Shareholders
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2010
T-Ray Science, Inc. Announces Management Appointments
Devices Personnel

HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2010
FDA Approves Zyclara(TM) (imiquimod) Cream, 3.75% for the Treatment of Actinic Keratoses
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 May 2009
DUSA Initiates Clinical Trial of Levulan(R) PDT on High-Risk Solid Organ Transplant Recipients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Mar 2009
Neoprobe's Phase 3 Lymphoseek Study Achieves Positive Results
Devices Oncology

HSMN NewsFeed - 18 Mar 2009
Breast-Specific Gamma Imaging (BSGI) Can Reduce the Number of Unnecessary Breast Biopsies When Compared to MRI
Devices Radiology Oncology

HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Feb 2009
Neoprobe Hires V.P. of Pharmaceutical Research & Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Sep 2008
Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Jul 2008
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jun 2008
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 9 Jun 2008
Neoprobe Commences Lymphoseek Phase 3 Trial
Diagnostics

HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Apr 2008
Graceway Pharmaceuticals Reports Study in New England Journal of Medicine: ALDARA(R) (imiquimod) Cream, 5% demonstrated a reduction in lesion size in patients with vulvar intraepithelial neoplasia (VIN)
Biopharmaceuticals

HSMN NewsFeed - 16 Apr 2008
Neoprobe Receives Regulatory Clearance for Lymphoseek Clinical Study
Diagnostics FDA

HSMN NewsFeed - 16 Apr 2008
Neoprobe Receives $3 Million in Clinical Funding
Diagnostics

HSMN NewsFeed - 10 Mar 2008
GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2008
APP Pharmaceuticals Receives FDA Approval for Bleomycin Sulfate for Injection, USP
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Oct 2007
Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2007
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Sep 2007
Aranesp(R) DAHANCA 10 Study Results Presented at ECCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Sep 2007
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmacetuicals Oncology

HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing

HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jun 2007
Taxotere(R) (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 19 Jun 2007
Inovio Biomedical's Selective Electrochemical Tumor Ablation Therapy Shows Safety, Tolerability, and Significant Complete Responses in Breast Cancer Study
Devices Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jun 2007
CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
Inovio Biomedical Stops Enrollment of Phase III Clinical Trials for Head & Neck Cancer
Devices Drug Delivery Oncology

HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
New Study Finds that Reflective Confocal Microscopy May Be a Feasible Alternative in the Diagnosis of Actinic Keratoses
Devices Dermatology

HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Feb 2007
GSK Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Feb 2007
Inovio Presents MedPulser(R) Electrochemical Tumor Ablation Results at 5th International Symposium on Advances in Head & Neck Cancer
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 23 Jan 2007
DUSA Pharmaceuticals, Inc.: International Guidelines Recommend Photodynamic Therapy as First-Line Treatment for Actinic Keratoses
Biopharmaceuticals Dermatology

HSMN NewsFeed - 16 Jan 2007
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Oct 2006
Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Sep 2006
Genmab Initiates HuMax-EGFr Pivotal Study In Refractory Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 May 2006
Introgen to Announce Important New Clinical Data for ADVEXIN Cancer Therapy at Major Medical Meetings
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
CEL-SCI Presents Long-Term Survival Data With Its Anti-Cancer Drug Multikine(R)
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 62

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 62 additional stories matching:
squamous cell carcinoma
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.